Mironid

Mironid is a biopharmaceutical company developing small molecule therapies for life-threatening inherited kidney diseases. Its lead program focuses on Autosomal Dominant Polycystic Kidney Disease (ADPKD), characterized by the growth of fluid-filled cysts and recognized as the most common inherited kidney disorder, yet with limited treatment options. Its small molecule LoAc® candidate directly targets abnormally high renal cAMP levels that drive cyst formation.